Alpha-1 lung disease is a term commonly used for lung problems caused by alpha-1 antitrypsin deficiency (AATD), an inherited condition that can increase the risk of emphysema and chronic obstructive pulmonary disease (COPD). The condition can affect people differently, and lung damage may develop earlier than expected in some individuals. Treatment is individualized. Avoiding tobacco smoke is especially important, while inhaled medicines, pulmonary rehabilitation, vaccinations, oxygen therapy, and other COPD treatments may be used according to the severity of lung disease. Selected patients with severe deficiency and established airflow obstruction may also be considered for intravenous augmentation therapy.
Alpha-1 antitrypsin is a protein produced mainly by the liver. It helps protect lung tissue from enzymes released during inflammation.
In alpha-1 antitrypsin deficiency, inherited changes in the SERPINA1 gene can result in low levels of functional alpha-1 antitrypsin in the bloodstream. Without sufficient protection, lung tissue may become more vulnerable to long-term damage.
Smoking and exposure to other lung irritants can significantly increase the risk of developing serious lung disease in people with AATD.
Symptoms can resemble those of COPD or emphysema and may include:
Some people develop symptoms relatively early in adulthood, while others remain symptom-free for many years.
The lungs contain millions of tiny air sacs called alveoli that help exchange oxygen and carbon dioxide.
When alpha-1 antitrypsin protection is insufficient, inflammation-related enzymes can contribute to destruction of lung tissue. This can cause emphysema, reducing the lungs' ability to move oxygen efficiently.
AATD-related emphysema may have a different distribution in the lungs compared with typical smoking-related emphysema, although patterns can vary.
Alpha-1 antitrypsin deficiency is an inherited risk factor for COPD.
COPD associated with AATD can cause progressive airflow limitation and breathing difficulties. People who smoke can experience substantially faster lung-function decline, which is why avoiding tobacco exposure is particularly important.
Not everyone with AATD develops COPD.
Healthcare professionals may consider AATD testing in people with:
Because AATD is inherited, identifying one affected family member may lead to testing for relatives.
A blood test can measure the amount of alpha-1 antitrypsin circulating in the body.
Additional testing may include:
Pulmonary function testing can measure airflow and help determine how significantly the lungs are affected.
Genetic testing can identify specific SERPINA1 variants and help clarify the type of deficiency.
There is currently no routine treatment that removes the inherited genetic cause of AATD. However, treatment can help manage lung disease and reduce additional damage.
Avoiding cigarettes and secondhand smoke is one of the most important measures for protecting lung function.
Exposure to workplace dust, chemical fumes, air pollution, and other respiratory irritants may also need to be minimized.
People with airflow obstruction may receive inhaled medicines commonly used for COPD.
Bronchodilators can help relax airway muscles and improve airflow. Other inhaled treatments may be recommended depending on symptoms and the presence of additional respiratory conditions.
Pulmonary rehabilitation combines supervised exercise, breathing techniques, education, and lifestyle support.
It may help improve exercise capacity and reduce the impact of chronic breathing difficulties.
Intravenous alpha-1 proteinase inhibitor therapy, commonly called augmentation therapy, can raise alpha-1 antitrypsin levels in the bloodstream.
It may be considered for selected people with severe AATD and established lung disease. Eligibility depends on factors such as the specific genetic deficiency, blood protein levels, lung function, and clinical recommendations.
Augmentation therapy is not a replacement for standard COPD care or avoidance of smoking.
Some people with advanced lung disease develop persistently low blood oxygen levels.
Long-term oxygen therapy may be prescribed when testing shows that oxygen levels are sufficiently low to benefit from supplemental oxygen.
In severe, advanced lung disease, lung transplantation may be considered for carefully selected patients.
This is generally reserved for situations in which lung function has become severely impaired despite other treatments.
Lifestyle measures can play an important role in protecting lung health.
Helpful measures may include:
A healthy lifestyle cannot correct the underlying genetic deficiency, but it may help reduce additional stress on the lungs.
Although alpha-1 lung disease primarily refers to respiratory complications, AATD can also affect the liver.
Certain abnormal alpha-1 antitrypsin proteins can accumulate inside liver cells and contribute to inflammation and scarring.
Possible liver complications include:
For this reason, people with confirmed AATD may require both lung and liver monitoring.
The outlook varies significantly.
Some people with AATD never develop significant lung disease, while others develop emphysema or COPD earlier in life. Smoking history, genetic type, lung function, environmental exposures, and overall health can all influence the course of disease.
Early diagnosis can provide an opportunity to reduce preventable risk factors and establish appropriate monitoring.
Alpha-1 lung disease is an important inherited cause of emphysema and COPD that can sometimes be overlooked. The underlying problem is alpha-1 antitrypsin deficiency, which results from inherited changes affecting the SERPINA1 gene. Insufficient functional alpha-1 antitrypsin can leave lung tissue more vulnerable to damage caused by chronic inflammation.
Symptoms such as persistent shortness of breath, wheezing, chronic cough, reduced exercise tolerance, and repeated respiratory infections can resemble ordinary COPD or asthma. However, alpha-1 antitrypsin deficiency may be suspected when emphysema occurs at an unusually young age, develops without a typical smoking history, or occurs alongside unexplained liver disease or a family history of the condition.